Drug Trial Radar · NCT07944261
Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,324
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Apr 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- Shandong Provincial HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare two doses of a clot-dissolving medicine called tenecteplase (TNK), specifically recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA), in adults with a mild ischemic stroke that causes disabling symptoms. An ischemic stroke occurs when a blood clot blocks blood flow to the brain. Even a mild stroke can cause problems that prevent a person from carrying out basic daily activities or returning to work. The main question is whether a lower dose of rhTNK-tPA helps patients recover nearly as well as the standard dose, within a predefined acceptable difference. The study will also compare bleeding and other side effects between the two doses. Up to 1,324 participants at multiple hospitals will be randomly assigned to receive either the lower dose (0.18 mg/kg, up to 16 mg) or the standard dose (0.25 mg/kg, up to 25 mg). Each participant will receive one injection into a vein within 4.5 hours of stroke onset, along with usual stroke care. Participants and treating doctors will know which dose is given, but the assessors evaluating recovery will not. Participants will be followed for approximately 90 days. Researchers will assess recovery, ability to carry out daily activities, quality of life, bleeding, and other medical problems. The main outcome is the proportion of participants who have no symptoms or no significant disability at about 90 days after treatment.
Conditions
- Acute Ischemic Stroke
- Minor Ischemic Stroke
Interventions
Tenecteplase 0.18 mg/kgDrug
Tenecteplase (rhTNK-tPA) will be administered at 0.18 mg/kg, with a maximum dose of 16 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Tenecteplase 0.25 mg/kgDrug
Tenecteplase (rhTNK-tPA) will be administered at 0.25 mg/kg, with a maximum dose of 25 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-1Time frame: 90 ± 7 days after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.